Summit Therapeutics

About

Summit Therapeutics Inc. is a biopharmaceutical oncology company committed to the discovery, development, and commercialization of patient-, physician-, caregiver-, and societal-friendly medicinal therapies. The company's mission focuses on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs, particularly in the field of oncology. Headquartered in Miami, Florida, with additional offices in Palo Alto, California; Princeton, New Jersey; Oxford, UK; and Dublin, Ireland, Summit Therapeutics has positioned itself as a leader in cancer treatment innovation. The company's lead pipeline candidate is ivonescimab, a novel bispecific antibody targeting both PD-1 and VEGF. In January 2023, Summit established a collaboration and license agreement with Akeso, Inc. for ivonescimab, gaining rights to develop and commercialize the therapy in the United States, Canada, Europe, Japan, Latin America, the Middle East, and Africa. Summit is currently conducting multiple global Phase 3 clinical trials for ivonescimab, including studies in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). The company has initiated several Phase 3 trials including HARMONi, HARMONi-3, HARMONi-7, and HARMONi-GI3, demonstrating a commitment to advancing oncology treatment options. With a leadership team that has a proven track record in drug development, regulatory approval, and commercialization, Summit is positioning itself for durable growth while maintaining its focus on patient-centered innovation.